


A Herceptin® (trastuzumab) biosimilar available in Canada¹



Early Breast Cancer (EBC)^{1*}

PrHERZUMA® (trastuzumab) is indicated for the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2,

- following surgery and after chemotherapy
- following adjuvant chemotherapy consisting of doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel
- in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.

Metastatic Breast Cancer (MBC)^{1*}

HERZUMA® is indicated for the treatment of patients with MBC whose tumours overexpress HER2.

Biosimilar by design. Biologic by essence.

NEW INDICATION

HERZUMA® can be used in combination with pertuzumab and docetaxel for the treatment of patients with HER2-positive MBC who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.[†]

Metastatic Gastric Cancer (MGC)^{1*}

HERZUMA® in combination with capecitabine or intravenous 5-fluorouracil and cisplatin is indicated for the treatment of patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.

 **HERZUMA®: A proud offering from Teva Canada Innovation.**



* Indications have been granted on the basis of similarity between HERZUMA® and the reference biologic drug Herceptin®.

† For information on the use of HERZUMA® in combination with pertuzumab and docetaxel, consult the Product Monograph for pertuzumab.

HERZUMA® is available in a reduced size, single-dose 150 mg vial

DIN	02480794, 02506211
UPC	068510998859, 068510999214
Inventory item number	HERZUMA® 440 mg/mL intravenous (IV) infusion: 85010-0001 HERZUMA® 150 mg/mL IV infusion: 85009-0001
Drug category	Antineoplastic ¹
Dosage form	HERZUMA® is a sterile, white to pale yellow, preservative-free lyophilized powder for IV administration ¹
Drug amount	440 mg per vial or 150 mg per vial ¹
Route of administration	IV infusion ¹
Non-medicinal ingredients	440 mg/vial: L-histidine, L-histidine HCl, polysorbate 20, α,α -trehalose dihydrate, and Bacteriostatic Water for Injection (BWFI) containing 1.1% benzyl alcohol ¹ 150 mg/vial: L-histidine, L-histidine HCl, polysorbate 20, and α,α -trehalose dihydrate ¹
Reconstitution	440 mg/vial: Reconstitution with 20 mL of the supplied BWFI, containing 1.1% benzyl alcohol as a preservative, yields a multi-dose solution containing 21 mg/mL trastuzumab, at a pH of approximately 6 ¹ 150 mg/vial: Reconstitution with 7.2 mL of the Sterile Water for Injection (SWFI) (not supplied), yields a single-dose solution containing 21 mg/mL trastuzumab, at a pH of approximately 6 ¹
Availability	440 mg/vial: Each carton contains: ¹ • One vial of 440 mg HERZUMA® • One 20 mL vial of BWFI containing 1.1% benzyl alcohol 150 mg/vial: Each carton contains: ¹ • One vial of 150 mg HERZUMA®
Storage instructions	<ul style="list-style-type: none"> • HERZUMA® vials are stable at 2°C-8°C prior to reconstitution • Following reconstitution with BWFI, vials are stable for 28 days when stored refrigerated at 2°C-8°C • Discard any remaining reconstituted solution after 28 days • Discard any vial that is past the expiry date indicated on the label • If unpreserved SWFI (not supplied) is used, the reconstituted solution of HERZUMA® should be used immediately and any unused portion must be discarded • Do not freeze HERZUMA® that has been reconstituted¹

Contact your Teva Canada Hospital Key Account Manager or Oncology Specialty Representative at 1-800-268-4129 for more information.

For more information:

Please consult the Product Monograph at <https://www.tevacanada.com/globalassets/canada-scs/product-monographs/herzuma-approved-pm-e-16april21.pdf> for important information relating to contraindications, warnings, precautions, adverse reactions, drug interactions, dosing, administration and conditions of clinical use, which have not been discussed in this piece. The Product Monograph is also available by calling Teva Canada Innovation at 1-833-662-5644.

Reference: 1. ^{Pr}HERZUMA® Product Monograph. Teva Canada Limited. April 16, 2021.

Herceptin® is a registered trademark of Genentech Inc. used under license.

^{Pr}HERZUMA® is a trademark of Celltrion Healthcare Co., Ltd.

© 2021 Teva Canada Innovation G.P. - S.E.N.C. Montreal, Quebec, H2Z 1S8